Givosiran (Givlaari)
Keyword(s):
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses givosiran (Givlaari), 189 mg/mL, solution for subcutaneous injection. Indication: For the treatment of acute hepatic porphyria in adults.